Q4 EPS Estimate for Candel Therapeutics Boosted by Analyst

Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Brookline Capital Markets boosted their Q4 2026 EPS estimates for Candel Therapeutics in a report released on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.31) for the quarter, up from their prior forecast of ($0.32). The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.22) per share. Brookline Capital Markets also issued estimates for Candel Therapeutics’ Q1 2027 earnings at ($0.34) EPS, Q2 2027 earnings at ($0.35) EPS, Q3 2027 earnings at ($0.42) EPS and Q4 2027 earnings at ($0.42) EPS.

Several other brokerages have also recently commented on CADL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Thursday, October 15th. Jefferies Financial Group began coverage on shares of Candel Therapeutics in a research note on Thursday, October 22nd. They issued a “buy” rating and a $25.00 price target on the stock. Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Citigroup reduced their target price on shares of Candel Therapeutics from $26.00 to $20.00 and set a “buy” rating for the company in a report on Monday. Finally, Stifel Nicolaus decreased their price target on Candel Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, November 13th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.29.

Get Our Latest Report on Candel Therapeutics

Candel Therapeutics Stock Performance

Shares of NASDAQ:CADL opened at $5.32 on Tuesday. The company has a current ratio of 7.57, a quick ratio of 7.57 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $417.35 million, a P/E ratio of -3.59 and a beta of -0.27. The business has a 50-day moving average price of $9.33 and a two-hundred day moving average price of $8.39. Candel Therapeutics has a 1-year low of $4.35 and a 1-year high of $14.00.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CADL. BlackRock Inc. bought a new position in Candel Therapeutics during the second quarter worth about $51,181,000. Portolan Capital Management LLC raised its stake in Candel Therapeutics by 1.4% during the third quarter. Portolan Capital Management LLC now owns 3,538,561 shares of the company’s stock worth $36,943,000 after acquiring an additional 48,163 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Candel Therapeutics by 4.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 317,601 shares of the company’s stock valued at $3,316,000 after purchasing an additional 12,385 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Candel Therapeutics in the 2nd quarter valued at $2,873,000. Finally, Wellington Management Group LLP bought a new position in Candel Therapeutics in the second quarter valued at about $2,119,000. Institutional investors own 13.93% of the company’s stock.

More Candel Therapeutics News

Here’s some of the latest news about CADL:

  • Positive Sentiment: Zacks Research upgraded CADL from “strong sell” to “hold,” suggesting a less bearish view, though the new rating is not a buy recommendation. Zacks Research ratings
  • Positive Sentiment: HC Wainwright reiterated a “Buy” rating and an $18 price target, and raised its FY2026 loss forecast to a narrower $1.19 per share from $1.28. However, it also reduced several later-year earnings estimates. Analyst estimates and rating
  • Negative Sentiment: Despite its Buy rating, HC Wainwright lowered projected earnings for FY2027–FY2030, including cutting FY2029 EPS from $1.41 to $0.60 and FY2030 EPS from $2.07 to $1.31. The revisions temper the longer-term bullish outlook. HC Wainwright earnings estimates

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Featured Articles

Earnings History and Estimates for Candel Therapeutics (NASDAQ:CADL)

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.